Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, September 12, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, September 11, 2023
[ 12:00 AM ] - United States, WOPRAI
Eddie Hickman Maintained (TARS) at Strong Buy with Increased Target to $49 on, Sep 11th, 2023
Eddie Hickman of Guggenheim, Maintained "Tarsus Pharmaceuticals, Inc." (TARS) at Strong Buy with Increased Target from $46 to $49 on, Sep 11th, 2023.
Eddie has made no other calls on TARS in the last 4 months.
There is 1 other peer that has a rating on TARS. Out of the 1 peers that are also analyzing TARS, 0 agree with Eddie's Rating of Hold.
This is the rating of the analyst that currently disagrees with Eddie
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $42 on, Friday, August 11th, 2023
